NCT04971200 (TILDVIT-1227) is a EARLY_PHASE1 clinical trial of Tildrakizumab in Skin and Connective Tissue Diseases, sponsored by Premier Specialists, Australia.

Who is sponsoring NCT04971200?

NCT04971200 is sponsored by Premier Specialists, Australia.

What drugs are being tested in NCT04971200?

Interventions in NCT04971200: Tildrakizumab.

What condition does NCT04971200 study?

NCT04971200 studies Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder, Hypopigmentation, Biologic, Vitiligo.

Is NCT04971200 still recruiting?

NCT04971200 is currently completed. Last updated 12 November 2024.

Last reviewed 2024-11-12 · How we verify

NCT04971200: TILDVIT-1227

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

Completed EARLY_PHASE1 Last updated 12 November 2024

What this trial tests

EARLY_PHASE1 trial testing Tildrakizumab in Skin and Connective Tissue Diseases in 12 participants. Completed in 10 November 2024.

Timeline

16 September 2021

Primary endpoint
10 November 2024

10 November 2024

Quick facts

Lead sponsor	Premier Specialists, Australia
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	16 September 2021
Primary completion	10 November 2024
Estimated completion	10 November 2024
Sites	1 location across Australia

Drugs / interventions tested

Tildrakizumab (TILDRAKIZUMAB) — full drug profile →

Conditions studied

Skin and Connective Tissue Diseases — all drugs for Skin and Connective Tissue Diseases →
Skin Diseases — all drugs for Skin Diseases →
Pigmentation Disorder — all drugs for Pigmentation Disorder →
Hypopigmentation — all drugs for Hypopigmentation →

Sponsor

Premier Specialists, Australia — full company profile →

Who can join

18 and older, any sex, with Skin and Connective Tissue Diseases or Skin Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies.
Bezzio C, Cavalli CAM, Franchellucci G, Dal Buono A, et al · · 2024 · cited 3× · PMID 39575159 · DOI 10.1177/17562848241299564

Verify or expand the search:

Other trials of Tildrakizumab

Trials testing the same drug.

NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT07244744 — Tilrdakizumab Almirall · active not recruiting
NCT04823247 — Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - · completed
NCT03897075 — Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis · Phase 3 · completed
NCT04458311 — Abiraterone Acetate in Combination With Tildrakizumab · Phase 1, PHASE2 · terminated

Other recruiting trials for Skin and Connective Tissue Diseases

Currently open trials in the same condition.

NCT06427889 — Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes · Phase 4 · recruiting
NCT05525741 — Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients · NA · active not recruiting
NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting

Other Premier Specialists, Australia trials

Trials by the same sponsor.

NCT06032078 — Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris · NA · unknown
NCT05534776 — Validation of 5-Point Investigator Global Assessments for Pemphigus · unknown
NCT05535517 — Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris · unknown
NCT05525065 — Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs) · unknown
NCT07228481 — Study of Two Dosages of Roaccutane in Cystic Acne · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04971200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Premier Specialists, Australia
Last refreshed: 12 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing